Atara Biotherapeutics Inc (ATRA) - News Archive

Atara Biotherapeutics Announces Second Quarter 2025 Financial Results and Noteworthy Operational Progress in T-Cell Immunotherapy Development Thousand Oaks, Calif. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), renowned as...

Advancing Innovation: Atara Biotherapeutics Resubmits BLA for Groundbreaking T-Cell Therapy, Amidst Impressive Growth Atara Biotherapeutics, Inc. (Nasdaq: ATRA) is making waves in the biotech industry with an impressive...

Atara Biotherapeutics Soars Ahead: FDA Lifts Clinical Hold on EBVALLO (tabelecleucel) Program, Opening New Doors for T-Cell Immunotherapy Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneering force in T-cell immunoth...

In a landscape defined by rapid advancements in immunotherapy, Atara Biotherapeutics (Nasdaq: ATRA) stands out as a promising leader in T-cell immunotherapy, particularly through its pioneering allogeneic Epstein-Barr v...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a prominent player in the field of T-cell immunotherapy, has recently been in the spotlight following significant developments regarding its lead therapeutic candidate, EBVALL...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a prominent player in the field of T-cell immunotherapy, has recently announced its active participation in two prominent healthcare conferences: The Stifel 2024 Healthcare Co...

Atara Biotherapeutics, Inc. a prominent biotechnology company specializing in T-cell immunotherapy, has recently announced its participation in the upcoming Stifel 2024 Healthcare Conference. The company s President and...

Pioneering Innovation in T-Cell Immunotherapy: Atara Biotherapeutics Participates in Stifel 2024 Healthcare Conference In the ever-evolving landscape of biotechnology and pharmaceuticals, the emergence of cutting-edge t...

Transformative Strides in T-Cell Therapeutics: Atara Biotherapeutics Announces Financial Results and Operational Progress for Q2 2024 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a trailblazer in T-cell immunotherapy, ha...

Atara Biotherapeutics, a frontrunner in T-cell immunotherapy, is making significant strides in the development of revolutionary therapies for patients battling cancer and autoimmune diseases. The recent acceptance and p...

Atara Biotherapeutics Showcases Promising Preclinical Data for ATA3219 CAR T Therapy for Autoimmune Diseases at ISCT 2024 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneering entity in T-cell immunotherapy, has rele...

By Author Name Published in CSIMarket.com Thousand Oaks, Calif. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, has recently announced the submission of a Biologics License Application (BLA...